Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiac Biotech SolutionsCBSC EPS without NRI is $-0.00 as of Jun. 2025. Among 662 Medical Devices & Instruments companies, Cardiac Biotech Solutions ranks better than 84.59% on this metric.
Cardiac Biotech Solutions's earnings per share without non-recurring items for the
three
months ended in Jun. 2025 was $-0.00.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Cardiac Biotech Solutions's EPS without NRI or its related term are showing as below:
CBSC's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8.15 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Cardiac Biotech Solutions (OTCPK:CBSC) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Cardiac Biotech Solutions EPS without NRI Related Terms
Cardiac Biotech Solutions EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBSC vs LUCY, NXGL, MHUAF: EPS without NRI Comparison
For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiac Biotech Solutions PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Cardiac Biotech Solutions's PE Ratio without NRI falls into.
Cardiac Biotech Solutions EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiac Biotech Solutions (CBSC) has a EPS without NRI of $-0.00 as of Jun. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cardiac Biotech Solutions and its competitors. According to the industry distribution chart, Cardiac Biotech Solutions ranks #102 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 15.4%.
Is Cardiac Biotech Solutions' EPS without NRI too high?
Cardiac Biotech Solutions' current EPS without NRI is $-0.00. Based on the distribution chart, Cardiac Biotech Solutions ranks #102 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cardiac Biotech Solutions' EPS without NRI compare to LUCY and NXGL?
According to the Medical Devices & Instruments industry distribution chart, Cardiac Biotech Solutions ranks #102 out of 662 companies for EPS without NRI. This places Cardiac Biotech Solutions in the top 15% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 8.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cardiac Biotech Solutions and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiac Biotech Solutions's current EPS without NRI is $-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current EPS without NRI of $-0.00. The current EPS without NRI is $-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current EPS without NRI is $-0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBSC has been successfully added to your 
